In a small retrospective cohort of NSCLC patients receiving PD-1 treatment, high levels of pretreatment serum VEGF were a significant predictor of shorter progression free survival, especially in elderly (> 75 years) and ECOG PS 2 patients [57]. This evidence concerns the gene VEGFA and non-small cell lung carcinoma.